neurodegenerative diseases

In a proof-of-concept study, the test detected five key biomarkers of Alzheimer’s disease—more than current commercially available blood tests can measure

Prior to the MSDA Test, disease management in MS relied primarily on clinical assessments and MRI

Better diagnostics for neurodegenerative diseases can improve clinical trials to help move groundbreaking therapies to approval

Mount Sinai Health System among the first in the world to use blood tests as an early detection tool for Alzheimer’s disease and related dementias in patients

Analysis of microRNA sequences from hundreds of patient samples allowed researchers to develop a unique “ALS fingerprint”

Occupations with high metal exposure were also associated with an elevated risk for ALS

The study compared the accuracy of leading commercial blood tests in detecting amyloid plaques, a characteristic feature of Alzheimer’s

Treatment for giant axonal neuropathy was well tolerated and slowed loss of motor function

Simple test detects the key biomarker in neurodegenerative diseases that could lead to earlier diagnosis and accelerate drug development

Identifying and quantifying cryptic protein aggregates may help diagnose and develop therapies for brain disorders